Objectives To evaluate the effect of pharmacist's directed services (reconciliation plus counselling) on reducing medication discrepancies and improving patient's outcomes at discharge from hospital. Methods During the 3-month study period, 200 patients were randomly selected from internal medicine department from Jordan University Hospital (JUH) and allocated into two groups (intervention and control groups). The number and types of medication discrepancies were identified at admission. Then, pharmacist implemented medication reconciliation and medication counselling services to the intervention group patients. At discharge, the number of unintentional discrepancies was evaluated for both groups. Patients were assessed at 1 month following their discharge for any subsequent hospital readmissions, emergency department visits or side effects of medication therapy. Key findings The total number of identified unintentional discrepancies was 84 for the intervention group compared with 60 discrepancies for the control group. Omission and addition represented the most common types of discrepancies for both groups. Of the 84 recommendations submitted by pharmacists, clinicians accepted 78 cases (92.8%), and implemented only 46 recommendations (54.7%). At discharge, a significant reduction in the number of unintentional discrepancies was achieved for the intervention group, Pvalue (0.014), while no significant change was found for the control group, Pvalue = 0.508. One month postdischarge, a significantly higher number of patients in the control group reported experiencing side effects compared with the intervention group, Pvalue = 0.020. Conclusion The presence of clinical pharmacists in hospital wards had a promising effect on decreasing the number of medication errors and improving health outcomes.
Introduction
Medication reconciliation is a technique used by healthcare providers at different care settings to prevent medication errors. [1] According to the Institute for Safe Medication Practices Canada (ISMP Canada), medication reconciliation is defined as 'a formal process in which healthcare providers work together with patients, families and care providers to ensure accurate and comprehensive medication information is communicated consistently across transitions of care'. [2] ISMP Canada has described the process of medication reconciliation as 'a systematic and comprehensive review of patient's Best Possible Medication History (BPMH) to identify any possible medication discrepancies and to inform and enable prescribers to make the most appropriate prescribing decisions for the patient to solve identified discrepancies'. [2] Pharmacists are the healthcare providers responsible for providing optimal pharmaceutical care services. [3] Regular medication review and medication reconciliation, beside the development of patient care plan, are considered as important pharmaceutical care tools. [4] The Institute of Medicine reports acknowledged pharmacists as an essential resource of information on medication safe use, and their vital participation during hospital rounds as it improves medication safety. [5] Currently, all hospitals have a pharmacy department to ensure that all patients receive their medications in the correct way by implementing the eight rights of medication administration (right patient, right medication, right dose, right route, right time, right documentation, right reason and right response). Clinical pharmacists can ideally influence physicians on their prescribing of medicines because they have the appropriate knowledge regarding therapeutics and are in continuous contact with them. [6] Pharmacists have an important role in reducing discharge medical errors and patients' rehospitalization. [6] Clinical pharmacists were found aware of the importance of their role in providing medication reconciliation. [7] Several previous studies have investigated the impact of a pharmacist-provided medication reconciliation service on medication discrepancies in the hospital settings. Results showed that pharmacists were able to identify a range of 1.5-2.3 unintentional discrepancies per patient, [8] [9] [10] leading to a significant reduction of 40-75% of the total identified medication discrepancies. [9, 10] No previous study has investigated the outcomes of involving the clinical pharmacist in a medication reconciliation service in Jordan.
Acknowledging the importance of evaluating the value of medication reconciliation services in the different healthcare settings, this study was designed with the aim to assess the role of the pharmacist in providing a medication reconciliation service during the transition to and from the hospital setting in Jordan and to evaluate the effect of providing the service on reducing medication discrepancies, and improving patient's outcomes.
Methods Study design, participants and clinical setting
This randomized controlled study was conducted between April and July 2017 at the Jordan University Hospital (JUH), a 550 beds' tertiary teaching hospital located in Amman, the capital of Jordan.
During the study period, 200 patients who fulfilled the inclusion criteria were approached and asked to participate in the study. Inclusion criteria were as follows: age ≥18 years, using at least four regular pre-admission medications, with more than 48 h expected length of stay in the hospital, speaks Arabic, has no cognitive deficiency and not involved in any other clinical trial. Patients were excluded if they were in isolation, discharged within 24 h of admission, discharged against medical advice, unable or unwilling to provide written informed consent, unable to provide a personal phone number and also patients who were enrolled were ineligible for re-inclusion in the study if they were admitted to JUH a second time during the study period.
Ethical approval from the Institutional Review Board (IRB) at the Jordan University Hospital (JUH) was obtained (Reference number: 65/2017).
Data collection and identification of medication discrepancies
Data were collected by a well-trained pharmacists (one of the authors) who received an extensive training about how to conduct a reconciliation service. Patients were recruited from all internal medicine department subdivisions at JUH. For each recruited patient, a preprepared validated data collection form was used for data collection. [11] Patient-specific data include demographic data, administrative data, medical related data and BPMH. BPMH including pre-admission medications was collected from the patients' medical records, followed by interviewing the patient (or their caregivers) and finally by interviewing the responsible clinicians (details about data collection are presented in a previously published study). [11] For each patient, comorbidity was calculated using Charlson Comorbidity Index (CCI). This index represents a tool that is used to predict the 10-year mortality rate in individuals with comorbid conditions. [12] Following data collection, a comparison between patients' current admission medications and patient's preadmission medications was made to identify any discrepancies between the two medication lists. Discrepancies were categorized into dose discrepancies, frequency discrepancies, addition of a new drug, duplication of drugs, omission of drugs or using wrong drugs.
Identified discrepancies were then classified into documented or undocumented discrepancies. Documented discrepancies were defined as any change in medications that were justified in the patient's medical file. If the discrepancy was undocumented, the pharmacist reviewed the differences with the clinician to verify if the changes were intentional or made by error. In case of intentional discrepancies, the problem was recorded as a 'documentation error'. Otherwise, unintentional discrepancies were considered 'medication errors'.
Unintentional discrepancies (medication errors) were classified into three classes based on the level of their seriousness as described by Cornish and others: [13] 'class 1 discrepancies were those unlikely to cause patient discomfort or clinical deterioration. Class 2 discrepancies were those with the potential to cause moderate discomfort or clinical deterioration, and class 3 discrepancies were those with the potential to cause severe discomfort or clinical deterioration'. Discrepancies were classified by the two researchers of the study, and in the case of disagreement on classification, the discrepancy was discussed until consensus was reached.
Pharmacist-delivered intervention
Following medication discrepancy identification, patients were divided randomly into two groups, intervention and control. Patients were assigned to their groups based on Statistical Package for Social Science (SPSS) version 22 generated random table for assignment (SPSS Inc., Chicago, IL, USA) ( Figure 1 ).
For patients in the intervention group, upon identification of drug discrepancies, pharmacist responsible for enrolment intervened by contacting the responsible clinician using a structured written consult form. The number of accepted recommendations by the clinicians was documented and recorded. When the researcher suggests resolving an identified discrepancy and the responsible clinicians accept the suggestion is called an accepted recommendation (just an acceptance without any correction), if the accepted suggestion is implemented, then this is called implemented recommendation.
At discharge, the number of medication discrepancies was assessed again for both groups. Also, the pharmacist provided intervention group patients with education about their medications, including: information about efficacy/side effects of medications, proper use and storage of medications, the importance of adherence, medication changes made while in hospital (i.e. reviewing pre-admission medications vs. medications at discharge).
The evaluation of carry-over effect of pharmacists' intervention on the number of discrepancies over months was also assessed.
Follow-up assessment
One month following discharge, phone calls to all patients were conducted by the pharmacist to assess for any hospital readmissions, emergency department visits and side effects during the previous 1 month.
Statistical analysis
Data were entered and analysed using Statistical Package for Social Science (SPSS) version 22 (SPSS Inc.). Descriptive analysis was performed using mean and standard deviation (SD) for continuous variables and percentage for categorical variables. Checking for normality was carried out using Shapiro-Wilk test, with P-value ≥0.05, indicating normally distributed continuous variables.
Group differences between control and intervention groups were conducted using independent sample t-test/ Mann-Whitney U-test (depending on data normality) or using chi-square/Fisher's exact test when appropriate. A paired t-test/Wilcoxon sign rank test was performed to ascertain whether pharmacist's recommendations were effective in reducing the number of medication discrepancies. An analysis of trend was carried out using one-way ANOVA to evaluate the trend in change in the number of discrepancies over the study period (to evaluate the carryover study effect).
A P-value of <0.05 was considered statistically significant, and all tests were two-tailed.
Results
Demographic and medical characteristics of the study groups During the study period, 280 patients were screened, of whom 200 were approached for study inclusion; all patients agreed to participate in the study (100% response rate). Among those patients, 102 (51.0%) were allocated to the intervention group, while the remaining 98 (49.0%) were allocated to the control group. Tables 1 and 2 describe the demographic characteristics of the study groups. No significant differences were found between the two groups in terms of demographic characteristics. Average age was 63.1 years (SD 14.6) of the study participants and men represented half of patients in both groups (111, 55.5%). Most of the patients were married, and about half of them had educational level of diploma or higher. The majority of patients reported a monthly income below 750 JD (one American dollar equals 0.71 Jordanian Dinar (JD)) in both groups.
Regarding medical characteristics, no significant differences between the two groups were found in terms of the number of pre-admission medications (P-value = 0.195), the number of admission medications (P-value = 0.794), number of medical conditions (P-value = 0.714) and length of hospital stay (P-value = 0.413).
Patients were recruited from the different internal medicine departments involved in the study, with the majority of patients recruited from the respiratory department (37.3% for intervention group (n = 38) and 24.5% for control group (n = 24)). No significant difference in patient comorbidity was found between the two groups as evident by CCI values (P-value = 0.525).
Identified medication discrepancies among the study groups Table 3 shows the results of the identified medication discrepancies on admission for both the intervention and control groups. The total number of identified discrepancies for both groups was 412. Among them, there were 234 (56.8%) discrepancies for the intervention group and 178 (43.2%) for the control group. Regarding the unintentional discrepancies, the number was slightly higher for the intervention group (84 discrepancies with an average of 0.8 (SD 0.9)) compared with the control group (60 discrepancies with an average of 0.6 (SD 0.9)), but this difference was not statistically significant (P-value = 0.107). Similar findings were found for the intentional discrepancies (documentation errors). The seriousness of medication discrepancies was determined for both groups, and results showed no significant difference between the two groups (P-value 0.403). Moderate to severe harmful discrepancies (classes 2 and 3) represented 78.7% (n = 66) from the total number of the unintentional discrepancies for the intervention group, while 51.7% (n = 31) of the unintentional discrepancies were found moderate to severe for the control group. Figure 2 shows the most common type of identified unintentional discrepancies for both groups. For the intervention group, the most common discrepancies were omissions (36, 42.9%) followed by addition of a new drug (24, 28.6%). While for the control group, the most common discrepancies were addition of a new drug (37, 61.7%), followed by omissions (16, 26.7%). Omission and addition discrepancies represented 71.5% of all discrepancies among the intervention group and 88.4% among the control group.
Resolving unintentional medication discrepancies
During the study period, the pharmacist submitted 84 recommendations to the clinicians to resolve the identified Clinical significance of the pharmacist's directed services (medication reconciliation and patient education) at discharge
As a consequence of pharmacist's recommendations, results revealed a statistically significant reduction in the number of unintentional discrepancies in the intervention group, decreasing from 0.82 (SD = 0.95) at admission to 0.58 (SD = 1.31) at discharge, P-value (0.014). While in the control group, no significant change was found (0.61 (SD = 0.89) at admission vs. 0.82 (SD = 1.39) at discharge, P-value = 0.508; Figure 3 .
Evaluation of the carry-over effect of pharmacists' intervention on the number of discrepancies over months
Results from the analysis of trend revealed a linear relationship between the month of admission and the average number of unintentional discrepancies on admission for all patients (P-value for linear contrast test = 0.008). Such outcome proves that a somewhat linear decrease in the mean number of unintentional discrepancies over the study period existed, where the average number of medication discrepancies decreased from 1.15 in April to 0.53 in June (P-value for ANOVA test = 0.019).
Follow-up assessment
Postdischarge followed up results showed no significant differences in the number of patients who reported visiting the emergency department (n = 8 (7.8%) for intervention group vs n = 15 (15.3%) for control group; P-values = 0.098) or who were readmitted into hospital department (n = 3 (2.9%) for intervention group vs n = 7 (7.1%) for control group; P-value = 0.207). However, a significantly higher number of patients in the control group reported experiencing side effects compared to patients in the intervention group (n = 20 (20.4%) vs n = 9 (8.8%), respectively, P-value = 0.020).
Discussion
Medication reconciliation service is an important service provided by healthcare providers to ensure accurate medication lists during transition of care. This study examined the impact of direct pharmacist engagement in the service at admission to reduce medication discrepancies and to improve patient's outcomes. Up to the researchers' knowledge, this is the first study to be conducted in Jordan to evaluate the value of this effective pharmaceutical care service. Results of this study add to the literature in this area, highlighting the important role of the pharmacist in Table 3 The average number of identified discrepancies on admission for both the intervention and control groups
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detecting medication discrepancies and in preventing medical errors in the hospital setting. [14] [15] [16] [17] The findings of this study showed that unintentional medication discrepancies are common at the time of hospital admission for both control and intervention groups. During a 3-month period, the pharmacist was able to identify an average of 0.8 discrepancies per patient for the intervention group, and 0.6 unintentional medication discrepancies per patient for the control group. The overall average of medication discrepancies is relatively lower than that identified in previous studies. [8] [9] [10] This can probably be attributed to the recent accreditation the JUH owned in 2017 by the Joint Commission International (JCI). Most of the identified unintentional discrepancies for both groups involved omitting a drug or adding a drug. Similar finding was found in previous studies, where addition or omission of drugs was identified as the major types of medication discrepancies. [18] [19] [20] [21] Most of the identified unintentional discrepancies were stated as moderately to severely harmful discrepancies. Most of the unintentional discrepancies in the other studies were also stated as seriously harmful errors. [13, 22] Figure 3 Effect of pharmacist's directed medication reconciliation service on the number of unintentional discrepancies (a) control group (did not receive the reconciliation service) (b) intervention group (with reconciliation service provided). Comparisons were performed using the Wilcoxon sign rank test.
The identified unintentional discrepancies for the intervention group were communicated in a written format to the responsible clinician. Of the 84 interventions recommended, 93% were accepted. The acceptance rate of pharmacist's interventions was comparable to a study conducted in Spain (93%) [23] and higher than that obtained from a study implemented in Belgium (72%). [24] Despite the high acceptance rate of pharmacist's recommendations, 55% of pharmacist's recommendations were eventually implemented and resolved. In the Jordanian healthcare setting, the pharmacist is not permitted to make any changes on the patient's medication profile; only clinicians have the authority to update the patient's medication profile. Although hospital-based pharmacy services are still not fully developed in Jordan and other neighbouring countries, substantial willingness among clinicians and nurses to cooperate with pharmacists has been shown previously. [25, 26] Despite the humble implementation of pharmacist's recommendations, pharmacist's intervention in this study was associated with a significant reduction in the unintentional discrepancies for the intervention group compared with the control group. This may reflect on the important role pharmacists can play in resolving unintentional discrepancies on patient discharge. Several studies have shown significant improvements in patient safety through reduction in medication discrepancies as a result of pharmacist's involvement in a multidisciplinary healthcare team. [6, 20, 21, 27] In addition, study results showed that the average number of medication discrepancies decreased from 1.15 to 0.53 from the beginning to the end of the study. This important finding indicates a carry-over effect of pharmacist's recommendation over the 3-month study period. Such finding is not surprising considering the acknowledged input pharmacists have on patient care, and their positive effect on the clinicians' behaviour and recommendations. [28] The impact of the intervention on patient-related outcomes during the 1-month follow-up was very promising. There was a trend towards lower rehospitalization and emergency department visits by patients in the intervention group compared with the control group. In addition, a significantly lower incidence of side effects experienced by intervention group patients was reported compared to control group. Similar findings were established from other studies, as pharmacist-delivered reconciliation service influenced the health of patients by reducing side effects of their medications. [1, 6] A recently published meta-analysis showed a more substantial reduction in adverse drug event-related hospital revisits, emergency department visits and hospital readmissions for patients who received a pharmacist-delivered reconciliation service compared to patients who did not. [29] The success of the intervention delivered in this study was not only due to the medication reconciliation, but also the patient counselling delivered before discharge. A previous study by Al-Rashed et al. [30] showed that patient counselling by pharmacists prior discharge improved patients' knowledge of their prescribed medications, affecting their compliance rates and reducing selfprescription of medications from their home medicine stocks therefore leading to fewer hospital admissions and lower side effects.
This study has a number of limitations. Firstly, the study did not examine the effect of the pharmacist directed reconciliation service on reducing documentation errors. Secondly, this study was conducted in one hospital setting which may be affected by the hospital policy regarding pharmacists vs clinicians' roles in direct medication prescription and medication orders; thus, future studies need to be conducted in multiple and variant hospital settings in the country. Thirdly, the presence of the carry-over effect of pharmacist's recommendations was suggested to be associated with a reduction in the average number of discrepancies; however, other reasons cannot be ruled out, and thus, further investigation is needed to affirm this result. Fourthly, the study was not blinded, which may limit the validity of some of the outcomes assessed, particularly for the reported side effects between groups.
Conclusion
In conclusion, this study has focused on the important role of pharmacists in reducing medication discrepancies during transition of care. Study results shed light on the importance of pharmacists' engagement in providing the medication reconciliation service for inpatients, decreasing the number of medication errors and improving health outcomes.
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